Perspective: Opportunities in recalcitrant, rare and neglected tumors

Teicher,Beverly  A.

doi:10.3892/or.2013.2581

Perspective: Opportunities in recalcitrant, rare and neglected tumors

Authors:
- Beverly A. Teicher
View Affiliations

Affiliations: Molecular Pharmacology Branch, Developmental Therapeutics Program, National Cancer Institute, Rockville, MD 20852, USA
Published online on: July 2, 2013 https://doi.org/10.3892/or.2013.2581
Pages: 1030-1034
Copyright: © Teicher . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The ‘Recalcitrant Cancer Research Act of 2012’ defines recalcitrant cancers as having a 5-year survival rate of <20% and estimated to cause the death of at least 30,000 individuals in the US each year. Cancers specifically mentioned in the act are lung and pancreatic cancers. In addition to recalcitrant tumors, rare tumors are often neglected in the drug discovery arena. Sarcomas are ~1% of cancers. The NCI Specialized Programs of Research Excellence (SPOREs) provide disease-focused cancer center grants specifically to accelerate the impact of laboratory research on the treatment of patients. There are 3 SPOREs focused on pancreatic cancer, 7 SPOREs focused on lung cancer and 1 SPORE focused on sarcoma. Through the Developmental Therapeutics Program (DTP), NCI maintains the infrastructure and expertise for the operation of cell-free and cell-based high-, medium- and low-throughput assays. The current effort is on sarcoma, SCLC and pancreatic lines. The DTP functional genomics laboratory provides molecular analyses including gene expression microarrays, exon arrays, microRNA arrays, multiplexing gene assays, plus others as tools to identify potential drug targets and to determine the role of selected genes in the mechanism(s) of drug action and cellular responses to stressors. The DTP tumor microenvironment laboratory focuses on the discovery of targets and the development of therapeutic strategies targeting the tumor microenvironment and physiological abnormalities of tumors resulting from environmental factors or alterations in metabolic enzymes. The DTP maintains a group focused on determining the mechanism(s) of action and identifying potential surrogate markers of activity for select compounds integrating proteomics, transcriptomics and molecular biology platforms. In conclusion, the NCI has active SPORE programs and an internal effort focused on recalcitrant, rare and neglected cancers which are generating data toward improving treatment of these difficult diseases.

View Figures

View References

1	American Cancer Society. Cancer Facts and Figures 2011, 2012. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011.
2	American Cancer Society. Lung Cancer (Small Cell). 2012, http://www.cancer.org/cancer/lungcancer-non-smallcell.
3	Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jasssem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC and Thatcher N: Phase II study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naïve patients with extensive-stage small-cell lung cancer. J Clin Oncol. 27:4787–4792. 2009.PubMed/NCBI
4	Foster NR, Qi Y, Krook JE, Kugler JW, Kuross SA, Jett JR, Molina JR, Schild SE, Adjei AA and Mandrekar SJ: Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): findings based on North Central Cancer Treatment Group (NCCTG) trials. J Clin Oncol. 27(Suppl 15): 80852009.
5	van Meerbeeck JP, Fennell DA and De Ruysscher DKM: Small-cell lung cancer. Lancet. 378:1741–1755. 2011.
6	Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchnat N, Moore M, Pleskow D, Wang-Gillam A and Lowy AM: Changing the way we do business: recommendations to acclerate biomarker development in pancreatic cancer. Clin Cancer Res. 19:538–540. 2013. View Article : Google Scholar : PubMed/NCBI
7	Erkan M, Hausmann S, Michalski CW, Fingerle A, Dobritz M, Kleeff J and Friess H: The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 9:454–467. 2012. View Article : Google Scholar : PubMed/NCBI
8	Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 21:418–429. 2012. View Article : Google Scholar : PubMed/NCBI
9	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar
10	Teicher BA: Searching for molecular targets in sarcoma. Biochem Pharmacol. 84:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
11	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
12	Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, Tabata M and Tanimoto M: Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One. 4:e78352009.PubMed/NCBI
13	Johnson BE, Ihde DC, Makuch RW, Gazdar AF, Carney DN, Loe H, Russell E, Nau MN and Minna JD: myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest. 79:1629–1634. 1987. View Article : Google Scholar : PubMed/NCBI
14	Johnson BE, Russell E, Simmons AM, Phelps R, Steinberg SM, Ihde DC and Gazdar AF: MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem (Suppl). 24:210–217. 1996. View Article : Google Scholar : PubMed/NCBI
15	Shivapurkar N, Reddy J, Matta H, Sathyanarayana UG, Huang CX, Toyoka S, Minna JD, Chaudhary PM and Gazdar AF: Loss expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene. 21:8510–8514. 2002. View Article : Google Scholar : PubMed/NCBI
16	Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, Markovic A, Devereux WL, Ocasio CA, Chen JK, Stearns T, Thomas RK, Dorsch M, Buonamici S, Watkins DN, Peacock CD and Sage J: A critical requirement for Hedgehog signaling in small cell lung cancer. Nat Med. 17:1504–1508. 2011. View Article : Google Scholar : PubMed/NCBI
17	Watkins DN, Berman DM and Baylin SB: Hedgehog signaling: progenitor phenotype in small cell lung cancer. Cell Cycle. 2:196–198. 2003. View Article : Google Scholar : PubMed/NCBI
18	D’Angelo SP and Pietanza MC: The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther. 10:1–10. 2010.
19	Su G, Burant CF, Beecher CW, Athey BD and Meng F: Integrated metabolome and transriptome analysis of the NCI60 dataset. BMC Bioinformatics. 12(Suppl 1): S362011. View Article : Google Scholar : PubMed/NCBI
20	Sokilde R, Kaczkowski B, Podolska A, Cirera S, Gorodkin J, Moller S and Litman T: Global microRNA analysis of the NCI-60 cancer cell panel. Mol Cancer Ther. 10:375–384. 2011. View Article : Google Scholar : PubMed/NCBI
21	Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Lee JS, Garraway LA, Weinstein JN, Mills GB, Lee JS and Davies MA: Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell lines set. Mol Cancer Ther. 9:257–267. 2010. View Article : Google Scholar : PubMed/NCBI
22	Covell DG, Huang R and Wallqvist A: Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data. Mol Cancer Ther. 6:2261–2270. 2007. View Article : Google Scholar : PubMed/NCBI
23	Shoemaker RH: The NCI60 human tumor cell line anticancer drug screen. Nat Rev Cancer. 6:813–823. 2006. View Article : Google Scholar : PubMed/NCBI
24	Fer ND, Shoemaker RH and Monks A: Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1. J Exp Clin Cancer Res. 29:912010. View Article : Google Scholar : PubMed/NCBI
25	Muus U, Hose C, Yao W, Kosakowska-Cholody T, Farnsworth D, Dyba M, Lountos GT, Waugh DS, Monks A, Burke TR Jr and Michejda CJ: Development of antiproliferative phenylmaleimides that activate the unfolded protein response. Bioorg Med Chem. 18:4535–4541. 2010. View Article : Google Scholar : PubMed/NCBI
26	Jobson AG, Lountos GT, Lorenzi PL, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH and Pommier Y: Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 331:816–826. 2009.PubMed/NCBI
27	Monks A, Hose C, Pezzoli P, Kondapaka S, Vasant G, Petersen KD, Sehested M, Monteforte J and Shoemaker RH: Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs. 20:682–692. 2009. View Article : Google Scholar
28	Kosakowska-Cholody T, Cholody WM, Hariprakasha HK, Monks A, Kar S, Wang M, Michejda CJ and Carr BI: Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79. Cancer Chemother Pharmacol. 63:769–778. 2009. View Article : Google Scholar : PubMed/NCBI
29	Martinez JM, Sali T, Okazaki R, Anna C, Hollingshead M, Hose C, Monks A, Walker NJ, Baek SJ and Eling TE: Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative suppressor, inhibits tumor growth. J Pharmacol Exp Ther. 18:899–906. 2006. View Article : Google Scholar
30	Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH and Melillo G: Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res. 17:5123–5131. 2011.PubMed/NCBI
31	Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao L, Burger AM, Ziche M and Melillo G: Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1α expression in an AhR-independent fashion. Cancer Res. 70:6837–6848. 2010.PubMed/NCBI
32	Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH and Melillo G: Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 8:1867–1877. 2009. View Article : Google Scholar : PubMed/NCBI
33	Rapisarda A and Melillo G: Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol. 9:378–390. 2012. View Article : Google Scholar : PubMed/NCBI
34	Rapisarda A and Melillo G: Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 114:237–267. 2012. View Article : Google Scholar : PubMed/NCBI
35	Rapisarda A and Melillo G: Combination strategies targeting hypoxia inducible factor 1 (HIF-1) for cancer therapy. The Tumor Microenvironment. Series: Cancer Drug Discovery and Development. Bagley RG: Springer Science+Business Media, LLC; 2010, View Article : Google Scholar
36	Onnis B, Rapisarda A and Melillo G: Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 13:2780–2786. 2009. View Article : Google Scholar : PubMed/NCBI
37	Rapisarda A, Shoemaker RH and Melillo G: Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle. 8:4040–4043. 2009. View Article : Google Scholar : PubMed/NCBI
38	Rapisarda A and Melillo G: Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat. 12:74–80. 2009. View Article : Google Scholar : PubMed/NCBI
39	Stockwin LH, Yu SX, Stotler H, Hollingshead MG and Newton DL: ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer. 9:632009. View Article : Google Scholar : PubMed/NCBI
40	Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul G, Slade D, Galal A and Newton DL: Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer. 125:1266–1275. 2009. View Article : Google Scholar
41	Stockwin LH, Yu XY, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG and Newton DL: Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer. 127:2510–2519. 2010. View Article : Google Scholar : PubMed/NCBI
42	Han B, Stockwin LH, Hancock C, Yu SX, Hollingshead MG and Newton DL: Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor. J Proteome Res. 9:4016–4027. 2010. View Article : Google Scholar : PubMed/NCBI
43	Hancock CN, Stockwin LH, Han B, Divelbiss RD, Jun JH, Malhotra SV, Hollingshead MG and Newton DL: A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. Free Radic Biol Med. 50:110–121. 2011. View Article : Google Scholar : PubMed/NCBI
44	Orsburn BC, Stockwin LH and Newton DL: Challenges in plasma membrane phosphoproteomics. Expert Rev Proteomics. 8:483–494. 2011. View Article : Google Scholar : PubMed/NCBI
45	Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL and Newton DL: The ‘survivin suppressants’ NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol. 70:207–212. 2012.
46	Ye X, Chan KC, Prieto DA, Luke BT, Johann DJ, Stockwin LH, Newton DL and Blonder J: Trypsin-mediated ¹⁸O/¹⁶O labeling for biomarker discovery. Methods Mol Biol. 1002:133–149. 2013.PubMed/NCBI
47	Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA and Shoemaker RH: Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One. 7:e414012012. View Article : Google Scholar : PubMed/NCBI
48	Galal AM, Gul W, Slade D, Ross SA, Feng S, Hollingshead MG, Alley MC, Kaur G and ElSohly MA: Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. Bioorg Med Chem. 17:741–751. 2009. View Article : Google Scholar : PubMed/NCBI
49	Kaur G, Hollingshead M, Holbeck S, Schauer-Vukasinovic V, Camalier RF, Domling A and Agarwal S: Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic nautral product. Biochem J. 396:235–342. 2006. View Article : Google Scholar : PubMed/NCBI
50	Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE and Doroshow JH: Immunohistochemical detection of poly(ADP-ribose)polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther. 8:2004–2009. 2009. View Article : Google Scholar : PubMed/NCBI
51	Jobson AG, Cardellina JH, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R and Pommier Y: Identification of a bis-guanylhydrazone [4,4′-diacetyldiphenylurea-bis (guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Ckh2 kinase. Mol Pharmacol. 72:876–884. 2007.